Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock

Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock

Bibliographic Details
Main Authors:	Masip, Jordi, Mesquida, Jaume, Luengo, Cecilia, Gili, Gisela, Gomà, Gemma, Ferrer, Ricard, Teboul, Jean Louis, Payen, Didier, Artigas, Antonio
Format:	Online
Language:	English
Published:	Springer 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847092/

Similar Items

Increasing microcirculation after drotrecogin alfa (activated)
by: Donati, A, et al.
Published: (2007)

Introduction: severe sepsis and drotrecogin alfa (activated)
by: Artigas, Antonio, et al.
Published: (2007)

The safety profile of drotrecogin alfa (activated)
by: Fumagalli, Roberto, et al.
Published: (2007)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
by: Laterre, Pierre-François
Published: (2007)

Practical aspects of treatment with drotrecogin alfa (activated)
by: Camporota, Luigi, et al.
Published: (2007)

Drotrecogin alfa (activated): down and not out, but not really in either
by: Friedrich, Jan O, et al.
Published: (2006)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
by: Choi, Goda, et al.
Published: (2006)

Retrospective observational outcomes for drotrecogin alfa (activated)
by: Cameron, C, et al.
Published: (2007)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
by: Mackenzie, S, et al.
Published: (2004)

Drotrecogin alfa (activated) for the treatment of severe sepsis in adults
Published: (2006)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
by: Dhainaut, J, et al.
Published: (2008)

Skeletal Muscle Oxygen Saturation (StO2) Measured by Near-Infrared Spectroscopy in the Critically Ill Patients
by: Mesquida, J., et al.
Published: (2013)

Three years experience with drotrecogin alfa (activated) protein C in severe sepsis and septic shock at Salmaniya Medical Complex, Bahrain
by: Mohamed, H, et al.
Published: (2007)

Earlobe arterialized capillary blood gas analysis in the intensive care unit: a pilot study
by: Vaquer, Sergi, et al.
Published: (2014)

Operational evaluation of the earlobe arterialized blood collector in critically ill patients
by: Vaquer, Sergi, et al.
Published: (2015)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
by: Levy, Howard, et al.
Published: (2005)

Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis
by: Jamdar, Saurabh, et al.
Published: (2005)

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
by: Friedrich, Jan O, et al.
Published: (2006)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
by: Bernard, Gordon R, et al.
Published: (2003)

Drotrecogin alfa: start early, ensure response, stop early!
by: Jog, S, et al.
Published: (2008)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
by: Rowan, K, et al.
Published: (2007)

A large, single-centre UK registry of drotrecogin alfa-activated use
by: Macchiavello, L, et al.
Published: (2007)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
by: Beale, R, et al.
Published: (2007)

Eligibility for drotrecogin alfa therapy on the basis of APACHE II score and organ failure
by: Shulman, R, et al.
Published: (2005)

Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
by: Schuerholz, T, et al.
Published: (2004)

Što je atomska orbitala?
by: Marko Grba
Published: (2018-09-01)

New StoGuard Tape
Published: (2008)

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
by: Shorr, Andrew F, et al.
Published: (2010)

Defining the adequate arterial pressure target during septic shock: not a 'micro' issue but the microcirculation can help
by: Silva, Serena, et al.
Published: (2011)

Isoproterenol infusion and microcirculation in septic shock
by: Wiramus, S, et al.
Published: (2014)

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)
by: Macias, William L, et al.
Published: (2005)

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
by: Vincent, Jean-Louis, et al.
Published: (2006)

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
by: Friedrich, Jan O, et al.
Published: (2006)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
by: Gupta, Sanjay, et al.
Published: (2006)

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
by: Costa, Vania, et al.
Published: (2007)

Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
by: Launois, R, et al.
Published: (2002)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
by: Sadique, M Zia, et al.
Published: (2011)

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
by: Mirea, L, et al.
Published: (2011)

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
by: Williams, Mark D, et al.
Published: (2006)

Treatment of Severe Sepsis: Where Next? Current and Future Treatment Approaches After the Introduction of Drotrecogin Alfa
by: Rice, Todd W
Published: (2006)